These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26378777)

  • 21. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A roadmap for biomarker qualification.
    Warnock DG; Peck CC
    Nat Biotechnol; 2010 May; 28(5):444-5. PubMed ID: 20458313
    [No Abstract]   [Full Text] [Related]  

  • 23. An industry perspective on the US FDA biomarker qualification effort.
    Arnold ME
    Bioanalysis; 2018 Jun; 10(12):913-916. PubMed ID: 29923760
    [No Abstract]   [Full Text] [Related]  

  • 24. Biomarkers as drug development tools: discovery, validation, qualification and use.
    Kraus VB
    Nat Rev Rheumatol; 2018 Jun; 14(6):354-362. PubMed ID: 29760435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical product development and regulatory science for the 21st century: the critical path vision and its impact on health care.
    Buckman S; Huang SM; Murphy S
    Clin Pharmacol Ther; 2007 Feb; 81(2):141-4. PubMed ID: 17259935
    [No Abstract]   [Full Text] [Related]  

  • 26. Market watch: Upcoming catalysts in Q1 2015.
    Uribe A
    Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
    [No Abstract]   [Full Text] [Related]  

  • 27. A cost-effectiveness approach to the qualification and acceptance of biomarkers.
    Williams SA; Slavin DE; Wagner JA; Webster CJ
    Nat Rev Drug Discov; 2006 Nov; 5(11):897-902. PubMed ID: 17080026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Qualification of translational safety biomarkers.
    Sauer JM; Porter AC
    Exp Biol Med (Maywood); 2021 Nov; 246(22):2391-2398. PubMed ID: 33757340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA 2011 process validation guidance: lifecycle compliance model.
    Campbell C
    PDA J Pharm Sci Technol; 2014; 68(2):185-91. PubMed ID: 24668605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
    Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological mechanism-based drug safety assessment and prediction.
    Abernethy DR; Woodcock J; Lesko LJ
    Clin Pharmacol Ther; 2011 Jun; 89(6):793-7. PubMed ID: 21490594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FDA/critical path initiative/Duke-Margolis center for health policy public workshop on analytical validation of assays for biomarker qualification: an update on the White Paper.
    Piccoli SP
    Bioanalysis; 2018 Jun; 10(12):893-896. PubMed ID: 29924636
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarker definitions and their applications.
    Califf RM
    Exp Biol Med (Maywood); 2018 Feb; 243(3):213-221. PubMed ID: 29405771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurology and medical devices.
    Johnston SC; Hauser SL
    Ann Neurol; 2006 Oct; 60(4):11A-2A. PubMed ID: 17068793
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety biomarker applications in drug development.
    Schomaker S; Ramaiah S; Khan N; Burkhardt J
    J Toxicol Sci; 2019; 44(4):225-235. PubMed ID: 30944276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
    Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
    Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker Development Strategies - surmounting scientific and regulatory barriers in bringing innovative medicine to market.
    Shi M
    IDrugs; 2007 Apr; 10(4):246-8. PubMed ID: 17390245
    [No Abstract]   [Full Text] [Related]  

  • 40. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.